Shionogi Of Japan To Buy China’s C&O For $184.22 Million
This article was originally published in PharmAsia News
Japan's Shionogi said it plans to buy China's C&O Pharmaceutical Technology for about $184.22 million to increase its presence in the China market. The purchase agreement includes buying the 24.17% stake of Leo Star Development, a Chinese investment company
You may also be interested in...
France has announced a number of emergency measures to protect drug supplies threatened by the spread of the coronavirus.
Major generics companies have donated hydroxychloroquine sulfate doses for research and treatment of coronavirus. Companies are also donating hand sanitizer and personal protective equipment and are preparing to ramp up manufacturing and production.
Inovio forges ahead into Phase I trials with DNA-based vaccine candidate, but can it prove skeptics wrong?